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ABSTRACT
Blood transfusion is widely used in the clinic but the source of red blood cells (RBCs) is depen-
dent on donors, procedures are susceptible to transfusion-transmitted infections and complica-
tions can arise from immunological incompatibility. Clinically-compatible and scalable protocols
that allow the production of RBCs from human embryonic stem cells (hESCs) and induced plu-
ripotent stem cells (iPSCs) have been described but progress to translation has been hampered
by poor maturation and fragility of the resultant cells. Genetic programming using transcription
factors has been used to drive lineage determination and differentiation so we used this
approach to assess whether exogenous expression of the Erythroid Kr€uppel-like factor 1 (EKLF/
KLF1) could augment the differentiation and stability of iPSC-derived RBCs. To activate KLF1 at
defined time points during later stages of the differentiation process and to avoid transgene
silencing that is commonly observed in differentiating pluripotent stem cells, we targeted a
tamoxifen-inducible KLF1-ERT2 expression cassette into the AAVS1 locus. Activation of KLF1 at
day 10 of the differentiation process when hematopoietic progenitor cells were present,
enhanced erythroid commitment and differentiation. Continued culture resulted the appearance
of more enucleated cells when KLF1 was activated which is possibly due to their more robust
morphology. Globin profiling indicated that these conditions produced embryonic-like erythroid
cells. This study demonstrates the successful use of an inducible genetic programing strategy
that could be applied to the production of many other cell lineages from human induced plurip-
otent stem cells with the integration of programming factors into the AAVS1 locus providing a
safer and more reproducible route to the clinic. STEM CELLS 2016; 00:000–000
SIGNIFICANCE STATEMENT
Production of red blood cells from human pluripotent stem cells in the laboratory could solve
many of the problems associated with blood transfusion but clinical trials have been hampered by
the poor maturation status and fragility of differentiated cells. Here, we demonstrate the success-
ful use of an inducible transcription factor programing strategy that results in the enhanced differ-
entiation and maturation of red blood cells. This strategy could be applied to the production of
many other cell lineages from pluripotent stem cells with the integration of programming factors
into a safer harbor locus providing a safer and more reproducible route to the clinic.
INTRODUCTION
The generation of an unlimited supply of red
blood cells (RBCs) from human pluripotent
stem cells (hPSCs) such as human embryonic
stem cells (hESCs) or induced pluripotent stem
cells (iPSCs), could alleviate many of the cur-
rent problems facing the blood transfusion
services such as transfusion transmitted infec-
tion, donor supply and immune compatibility.
Scalable, clinically compatible protocols to pro-
duce erythroid cells from hPSCs have been
developed but progress to translation has
been hampered by the lack of terminal matu-
ration of the resultant cell. In contrast to RBCs
generated in vitro from adult bone marrow or
mobilised peripheral blood CD341 progenitors
cells, erythroid cells produced from both hESCs
and iPSCs have a fragile morphology, a poor
enucleation rates and express embryonic and
foetal rather than adult globin [1–7].
Transcription factors are arguably the most
important route to controlling cell type
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identity as they drive lineage-specific genes associated with
their functional properties [8]. Transcription factor program-
ming has been used to direct hESC/iPSC differentiation into
distinct cell types such as cardiomyocytes and neurons [9, 10].
Enhanced expression of transcription factors known to be
involved in the development and maintenance of the hemato-
poietic system such as SCL/TAL1, RUNX1, HOXA9, or HOXB4
have been used to increase the production of hematopoietic
stem/progenitor cells from hESCs/iPSCs [11–16] and four tran-
scription factors (GATA1, LMO2, SCL/TAL1, and cMYC) directly
converted fibroblast into primitive erythroid progenitors [17].
Erythroid Kruppel-like factor 1 (EKLF/KLF1) is a zinc finger
DNA binding protein that plays a critical role in regulating the
expression of genes involved in erythroid cell identity and
function including those involved in heme biosynthesis, red
cell membrane stability and adult globin [18, 19]. Coassocia-
tions of KLF1-regulated genes at specialized nuclear hotspots
is thought to optimize the coordinated transcriptional control
[20]
Detailed analyses of mouse mutants demonstrated that Klf1
deficiency results in defects in hemoglobin metabolism and
membrane stability and that KLF1-null erythroid cells in the fetal
liver have an abnormal morphology with many retaining their
nuclei [21–25]. Deficiencies in KLF1 have also been associated
with human disease [26, 27]. For example, a missense mutation
in KLF1 results in a dominant-negative congenital dyserythro-
poietic anemia [28]. Reduced activity of KLF1 has been associat-
ed with the rare blood group In (Lu) phenotype with amino acid
substitutions within zinc finger domains predicted to abolish
the interactions of KLF1 with downstream targets [29–31].
Genomic sequencing has uncovered the fact that a broad range
human red cell disorders are caused by variants in KLF1 [32].
We noted that KLF1 was expressed at a lower level in ery-
throid cells derived from hESCs compared to adult CD341-
derived cells and, given its importance in erythroid maturation,
we hypothesized this low level of expression of KLF1 might be
one reason for their lack of maturity. We first assessed the
effects of constitutive expression of KLF1 and noted a significant
reduction in the proliferative capacity of differentiating hESCs
and a high variability in expression and stability of the trans-
gene. We, therefore, developed a strategy where we could
induce activity of KLF1 at later time-points during the differenti-
ation process after hematopoietic progenitor cells (HPCs) had
formed by generating and testing a human KLF1-ERT2 fusion
protein. To achieve a consistent and physiological level of
expression and to avoid transgene silencing, we employed the
“safe harbor” approach by integrating the inducible KLF1-ERT2
transgene into the AAVS1 locus [33–35].
We show for the first time that the inducible activation of
KLF1 at a defined time point during the differentiation of both
hESC and iPSCs enhanced erythroid commitment and differentia-
tion. Continued culture of KLF1-activated cells resulted in a more
robust morphology and a higher proportion of detectable enu-
cleated cells. Globin profiling indicated that erythroid cells pro-
duced under these conditions had an embryonic-like phenotype.
MATERIALS AND METHODS
Plasmid Construction
cDNAs encoding human wild type KLF1 or mutant R328L KLF1
[31] were amplified by polymerase chain reaction (PCR) and
cloned into the EcoRI-digested pCAG-IRES-puro plasmid
(pCAG-SIP). Tamoxifen inducible KLF1-ERT2 and R328L-ERT2
fusion cassettes were generated by recombineering (Support-
ing Information Fig. S1B, S1D, S1E). CAG-HA-KLF1-ERT2-PolyA
was cloned into the multiple cloning site of the pZDonor-
AAVS1 Puromycin vector (PZD0020, Sigma-Aldrich, Gillingham,
UK, http://www.sigmaaldrich.com/).
Production of iPSCS from ORhesus Negative
Individuals
Dermal fibroblasts were obtained from blood group O Rhe-
sus negative individuals by R Biomedical Ltd, Edinburgh, UK,
(http://www.rbiomedical.com) under REC 1/AL/0020 ethical
approval. Fibroblasts were reprogrammed to iPSCs using an
episomal strategy with the transcription factors, OCT4, KLF2
SOX2, and cMYC [8] (http://roslincells.com). Characterization
of the SFCi55 cell line used in this study included flow
cytometry for key pluripotency and differentiation markers
(Supporting Information Fig. S2A, S2B). Chromosomal
spreads revealed a normal 46XX karyotype that was then
confirmed by SNP analysis (data not shown). Hematopoietic
differentiation of SFCi55 compared favorably to H1 hESCs
(data not shown) and other published iPSC lines (Supporting
Information Fig. S2C).
Maintenance and Differentiation of hESC and iPSCs
hESC and iPSCs were maintained in STEMPRO hESC SFM
(Thermo Fisher Scientific Life Sciences, Waltham, MA, http://
www.thermofisher.com) containing 20 ng/ml bFGF (FGF2)
(R&D Systems, Abingdon, U.K., https://www.rndsystems.com)
on CTS CELLstart Substrate (Thermo Fisher Scientific Life Sci-
ences) and passaged (1:4) when 70%-80% confluent using
STEMPRO EZPassage (Thermo Fisher Scientific Life Sciences,
Waltham, MA, http://www.thermofisher.com). Hematopoietic
differentiation was carried out in a step-wise, serum-, and
feeder-free protocol as described in detail previously [15, 36]
Transfection of hESC and iPSCs
H1 hESC or iPSCs were fed with STEMPRO hESC SFM contain-
ing 20 ng/ml bFGF, and 10 lM Rock inhibitor (Y-27632, Cal-
biochem, Darmstadt, Germany. http://www.merckmillipore.
com) was added at least 1 hour prior to electroporation as
described previously [11, 37]. Single cell suspensions were
generated using Accutase (Thermo Fisher Scientific Life Scien-
ces), washed and resuspended (107 cells per 0.5 ml) in Dul-
becco’s phosphate-buffered saline without Ca21 and Mg21
(DPBS) and electroporated with 30 lg of linearized vector
(BioRad Hemel Hempstead, UK http://www.bio-rad.com, Gene
pulser; 320V 250 lF). Cells were plated on CTS CELLstart sub-
strate in STEMPRO hESC SFM containing 20 ng/ml bFGF and
10 lM Rock inhibitor and 0.6 lg/ml puromycin for 10 days
then resistant colonies were picked, expanded, and screened
by PCR and Western blotting.
K562 Cell Maintenance and Electroporation
K562 cells were seeded at 105/ml in DMEM medium (Thermo
Fisher Scientific Life Sciences) supplemented with 10% fetal
calf serum, 2 mM sodium pyruvate (Thermo Fisher Scientific
Life Sciences), 1% nonessential amino acids (Thermo Fisher
Scientific Life Sciences), and 0.1 mM b-mercaptoethanol
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(Thermo Fisher Scientific Life Sciences) and passaged every 2-
3 days. K562 cells (107 cells in 700 ll DPBS) were electropo-
rated (BioRad, Gene pulser; 320 V, 500 lF), then pools of cells
were selected in 2.0 lg/ml puromycin (Sigma Aldrich) 2 days
later. Hemin (50 lM) (Sigma Aldrich) was added to the cul-
tures to induce differentiation then cells were harvested and
analyzed after 4 days.
COS7 Cell Maintenance and Transfection
COS7 cells were maintained in GMEM medium (Thermo Fisher
Scientific Life Sciences) supplemented with 10% fetal calf
serum, 2 mM sodium pyruvate (Thermo Fisher Scientific Life
Sciences), 1% nonessential amino acids (Thermo Fisher Scien-
tific Life Sciences), and 0.1 mM b-mercaptoethanol (Thermo
Fisher Scientific Life Sciences) and passaged at 1:5 ratio. Cells
were seeded at 5 3 104/well in a 6-well-plate and transfected
with 2.5 lg of DNA plasmid using the Xfect Transfection
Reagent (Clontech, Saint-Germain-en-Laye, France. http://
www.clontech.com).
Quantitative Reverse-Transcriptase Polymerase Chain
Reaction
RNA was extracted using RNeasy Mini Kit (QIAGEN), and
reverse transcription was performed by High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific Life Scien-
ces) following the manufacturer’s instructions. To normalize
cDNA quantity, GAPDH was used as reference gene. PCR reac-
tions were carried out in triplicate using Applied Biosystems
7500 Fast Real-Time PCR System and data was analyzed on
SDS v1.4 software (Thermo Fisher Scientific Life Sciences).
Protein Extraction and Western Blotting
Cells were lysed in RIPA buffer (Thermo Fisher Scientific Life
Sciences) for total protein extraction. For nuclear fraction-
ation, the cell pellet was resuspended in 0.2 ml of Swelling
Buffer (5 mM PIPES, pH 8.0; 85 mM KCL; 0.5% NP40; prote-
ase inhibitor cocktail) for 20 minutes on ice. After spinning
at 1,500 rpm at 48C, the cytoplasmic supernatant was
removed. The nuclear pellet was resuspended in 0.3 ml of
lysis buffer (20 mM Hepes, pH 7.6; 1.5 mM MgCl2; 350 mM
KCl; 0.2 mM EDTA; 20% Gycerol; 0.25% NP40; 0.5 mM DTT;
protease inhibitor cocktail; Benzonase) and gently shaken at
48C for 1 hour. The nuclear fraction was collected after cen-
trifuged at 13,000 rpm, 48C, for 30 minutes and stored at
2808C. Proper amount of protein lysates were electrophor-
esed on 4%-20% Ready Gel (BioRad), transferred to nitrocel-
lulose membranes (10402580, Whatman, Sigma Aldrich) and
probed with anti-HA tag (631207; Clontech), anti-KLF1
(sc14034, Santa Cruz, CA USA www.scbt.com), anti-GAPDH
(AF5718, R&D) antibodies or LaminB1 (ab16048, abcam,
Cambridge, UK, http://www.abcam.com). Antibody binding
was detected using the appropriate horseradish peroxidase-
conjugated IgG (HAF008, R&D Systems, Abingdon, U.K.,
https://www.rndsystems.com; sc-2020, SantaCruz) visualized
by the WesternSure ECL Substrate (LI-COR, Cambridge, UK,
https://www.licor.com).
CFU-C Assay
Day 10 differentiating cells (5 3 103 or 104) were plated into
1.5 ml of MethoCult (04435, Stem Cell Technologies, Cam-
bridge, UK, https://www.stemcell.com) in 35 mm low
attachment dishes (Greiner, Stonehouse, UK, https://www.
gbo.com), incubated at 378C in a humid chamber then scored
for hematopoietic colony formation 12-15 days later.
Flow Cytometry
105 differentiating cells were harvested in phosphate-buffered
saline (PBS) containing 1% bovine serum albumin (BSA) (PBS/
BSA) and centrifuged at 200 g for 5 minutes. Cell pellets were
resuspended and mixed with the appropriate volume of anti-
body, CD34-PE (12-0349-41, eBioscience, eBioscience Ltd., Hat-
field, UK, http://www.ebioscience.com/), CD43-APC (17-0439-
42, eBioscience), CD235a-FITC (11-9987-80, eBioscience), and
CD71-APC (17-0719-42, eBioscience), to a final volume of 100
ll PBS/BSA, incubated for 30 minutes then analyzed on a LSR
Fortessa (BD Biosciences, Oxford, UK, http://www.bdbioscien-
ces.com/) using FACS Diva. The proportion of enucleated cells
present in the culture was assessed using CD235a-FITC, CD71-
APC antibodies, LIVE/DEAD Fixable Near-IR Stain (L10119,
Thermo Fisher Scientific) and Hoechst dye (NucBlue, Thermo
Fisher Scientific). Live CD235a1 cells were first gated, then
anti-CD71 and Hoeschst were used to define erythroblasts
(CD711/Hoechst1), nucleated RBCs (CD712/Hoechst1) and
enucleated RBCs (CD712/Hoechst2) (Supporting Information
Fig. S7).
Immunofluorescence Staining
COS7 cells were fixed in 4% formaldehyde/PBS for 15 minutes
and permeabilized in 0.5% Triton-X 100/PBS (PBST) and suc-
cessively incubated for 1 hour with rabbit anti-human KLF1
(sc14034, Santa Cruz), goat anti–rabbit IgG-FITC (F0382-1ML,
SIGMA-ALDRICH) antibodies, and DAPI (4’,6-Diamidino-2-phe-
nylindole; SIGMA-ALDRICH). Stained cells were analyzed using
a Zeiss Observer microscope and processed with AxioVision
and ImageJ software.
Morphological Analysis
5 3 104 erythroid cells were resuspended in 0.2 ml PBS, load-
ed in cytospin slide chamber, and centrifuged at 500 rpm for
10 minutes. Rapid Romanowksy staining of air-dried slides
was performed according to manufacturer’s instructions
(HS705, TCS biosciences, Buckinghamshire, UK, http://www.
tcsbiosciences.co.uk).
High-Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) globin
chain separation was performed using a protocol modified
from Lapillonne et al. [38]. Briefly, cells were washed three
times in PBS, lysed in 50 ll water by three rapid freeze-
thaw cycles and centrifuged at 13,000 g at 48C for 10
minutes. Globin chain separation was performed by inject-
ing 10 ll of the supernatant onto a 1.0 3 250 mm C4
column (Phenomenex, Macclesfield, U.K., http://www.phe-
nomenex.com/) with a 42%-56% linear gradient between
mixtures of 0.1% TFA in water (Buffer A) and 0.1% TFA in
acetonitrile (Buffer B) at flow rate of 0.05 ml/min for 55
minutes on a HPLC Ultimate 3000 system (Dionex, Thermo
Fisher Scientific Life Sciences). The column temperature was
fixed at 508C during analysis and the UV detector was set at
220 nm. Elution times of peaks generated were compared
to control samples (e.g., adult and foetal blood) for
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identification and the area under the curve was used to cal-
culate the proportion of each globin peak as a percentage
of the total.
Statistical Analysis
The statistical analysis was performed using GraphPad
Prism 6 software. For cell proliferation (Figs. 1A, 4A) and
globin expression by HPLC (Fig. 6), data were analyzed
using two-way ANOVA followed by Tukey’s multiple
comparisons test. CFU-C (Fig. 1B) and flow cytometry
data (Figs. 1D, 3D, 7C) were analyzed using one-way
ANOVA followed by Holm-Sidak’s multiple comparison test.
Gene expression data were analyzed using ratio paired t
test.
Figure 1. Constitutive KLF1 expression in human embryonic stem cells (hESCs) results in reduced proliferation and hematopoietic pro-
genitor cell production. (A): Cell counts throughout the erythroid differentiation protocol of control H1 hESCs (H1) and H1 hESCs trans-
fected with a vector containing either wild type KLF1 (H1-KLF1) or the mutant form of KLF1 (H1-R328L). (B): Total number of CFU-Cs
generated from differentiating H1, H1-KLF1, and H1-R328L hESCs at day 10 of the differentiation protocol. (C): Flow cytometry analysis
of differentiating H1, H1-EKLF, and H1-R328L hESC at day 10 of the differentiation protocol using antibodies against CD34 and CD43 to
mark hematopoietic progenitor cells (HPCs). (D): Quantification flow cytometry data showing the %CD341/CD431 HPCs at day 10 of the
differentiation protocol. All data represents the mean of at least three independent experiments with error bars representing SEM. p
values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test (A) or one-way ANOVA followed by Holm-
Sidak’s multiple comparison test (B and D) (*p< .05).
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RESULTS
Constitutive Overexpression of KLF1 in Differentiating
hESCs Leads to Reduced Cell Proliferation and
Hematopoietic Progenitor Cell Production
KLF1 was expressed at a lower level in erythroid progenitors
derived from hESC compared to those derived from adult
peripheral blood CD341 progenitors (Supporting Information
Fig. S1A) and we hypothesized that this could be one of the
reasons for their lack of maturity. H1 hESCs were transfected
with vectors carrying either wild type KLF1 or mutant (R328L)
KLF1 cDNA under the control of the constitutive CAG promot-
er followed by an intraribosomal entry site and the puromycin
resistance gene (Supporting Information Fig. S1B). The R328L
mutant protein had an arginine (R) to leucine (L) substitution
in the second zinc finger domain at position 328 that abol-
ishes activity in a transactivation assay (Supporting Informa-
tion Fig. S1C) [29], but does not interfere with the activity of
WT KLF1. There was no significant difference in the morpholo-
gy of control H1, H1-KLF1, and H1-R328L hESC lines and all
cell lines were maintained as undifferentiated hESCs in com-
parable conditions (data not shown). The morphology of
transfected hESCs during the initial days of our erythroid dif-
ferentiation protocol [15, 36] was comparable to parental H1
hESCs but the proliferation rate at later stages of the differen-
tiation protocol was significantly lower in H1-KLF1 cells (Fig.
1A). There was a significant reduction in the total number of
CFU-C colonies detected in H1-KLF1 cells compared to control
H1 cells and H1-R328L cells (Fig. 1B). Flow cytometry con-
firmed the reduction in HPCs with fewer CD341 CD431 dou-
ble positive cells generated in the H1-KLF1 hESC line (Fig. 1C,
1D). Thus, constitutive expression of KLF1 resulted in a signifi-
cant reduction in the proliferative capacity and an associated
reduction in the production of HPCs hampering our ability to
assess the specific effects of KLF1 on erythroid differentiation
and maturation.
KLF1-ERT2 Fusion Protein Can Translocate to the
Nucleus and Can Activate KLF1 Target Genes upon
Induction
We established an inducible strategy where we could activate
KLF at specific time points during differentiation to assess the
effects of this transcription factor on later erythroid cell pro-
duction and maturation. We fused the human KLF1 and the
mutant KLF1 (R328L) to the mutated form of the oestrogen
receptor (ERT2) (Supporting Information Fig. S1D, S1E) and
created the expected sized fusion protein of 74 kD (Fig. 2A,
2B). Before investing resources on assessing this strategy on
Figure 2. Functional assessment of KLF1-ERT2 and R328L-ERT2 fusion proteins. (A, B): Western blot analyses of cell lysates isolated
from untransfected COS7 cells (lane 1), COS7 cells transfected with pCAG-KLF1 (lane 3); pCAG-R328L (lane 4); pCAG-KLF1-ERT2 (lane 5);
pCAG-R328L-ERT2 (lane 6) and the murine CAG- KLF1-ERT2 (lane 7) using an anti-KLF1 antibody (A) and GAPDH as a loading control (B).
Lane 2 is blank. (C, D): Immunofluorescence staining of COS7 cells transfected with either the CAG-KLF1-ERT2 (A) or CAG-R328L-ERT2 (B)
constructs then stained with anti-KLF1 antibodies (green) and the DAPI nuclear dye (blue) in the presence and absence of tamoxifen as
indicated. (Scale bar 10 lm). (E): Quantitative reverse-transcriptase polymerase chain reaction analyses of RNA isolated from control
and hemin and/or tamoxifen-treated K562 cells and K562 cells transfected with either CAG-KLF1-ERT2 or CAG-R328L-ERT2 vectors using
primers for the KLF1 target gene, AHSP. Data represent three independent experiments and error bars represent SEM. p values were cal-
culated using using one-way ANOVA followed Tukey’s multiple comparisons test. (*p< .05).
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hiPSCs, we first tested the functionality of the KLF1 inducible
strategy on simpler well-established cell systems. We used
transiently transfected COS7 cells where high levels of trans-
gene expression enable the subcellular location of fusion pro-
teins to be assessed by immunofluorescence staining. This
demonstrated that wild type KLF1-ERT2 and mutant R328L-
ERT2 fusion proteins are sequestered in the cytoplasm and,
upon tamoxifen treatment, they are released and can translo-
cate to the nucleus (Fig. 2C, 2D).
To assess whether the KLF1-ERT2 fusion protein could acti-
vate the expression of KLF1 target genes within a hematopoi-
etic context, we used the K562 human leukemia cell line that
could be induced to differentiate into the erythroid cells.
Pools of puromycin-resistant K562 cells were generated then
RNA was isolated after culturing in the presence or absence
of tamoxifen. Functionality of the KLF1-ERT2 fusion protein
was confirmed by demonstrating that the addition of tamoxi-
fen enhanced the expression level of a known KLF1 target
gene, Alpha Hemoglobin Stabilizing Protein (AHSP) (Fig. 2E).
No significant increase in AHSP expression was observed after
tamoxifen treatment of cells transfected with the CAG-R328L-
ERT2 construct confirming the lack of transcriptional activity of
the mutant form that had been predicted previously from
luciferase assays (Supporting Information Fig. S1C). Compara-
ble levels of KLF1-ERT2 and CAG-R328L-ERT2 protein were pro-
duced, excluding the possibility that that the lack of activity
of the mutant R328L-ERT2 was due to a lower level of expres-
sion (Fig. 2A).
Figure 3. Activation of KLF1 at day 10 of differentiation results in enhanced erythroid differentiation of hiPSCs. (A): Schematic of the
pZDonor-AAVS1 Puro-CAG-HA-KLF1-ERT2-PA construct. (B): Western blot analyses of nuclear cell lysates from adult CD341 cells that had
been differentiated for 6 days into erythroid progenitors, control undifferentiated and differentiated (day 10) induced pluripotent stem
cells (iPSCs), undifferentiated iKLF1.2 iPSCs and iKLF1.2 iPSC that had been differentiated for 10 days then treated with tamoxifen for 3
hours. Endogenous KLF1 and the expected larger sized KLF1-ERT2 fusion protein was detected with the anti-KLF1 antibody and the anti-
Lamin B1 antibody was used to detect nuclear proteins as a loading control. (C): Flow cytometry analysis using antibodies against
CD235a and CD71 of cells present at day 15 of the erythroid differentiation protocol in control iPSCs and iKLF1.2 iPSC cell lines in the
presence (1) and absence (2) of tamoxifen from day 10. (D): Quantitation of flow cytometry data representing three independent
experiments. Error bars represent SEM. p values were calculated using one-way ANOVA followed by Holm-Sidak’s multiple comparison
test (*p< .05). (E): Image showing the cell pellets from one representative experiment demonstrating a smaller but more intense red
pellet in the tamoxifen-treated iKLF1.2 cell line. Abbreviation: iPSCs, induced pluripotent stem cells.
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Activation of KLF1 Promoted Erythroid Differentiation
of hESC and iPSCs
We then tested the effects of KLF1 activation on the produc-
tion and maturation of erythroid cells during hESC and iPSC
differentiation. Pilot experiments where pCAG-KLF1-ERT2 and
pCAG-R382R-ERT2 constructs were randomly integrated into
the genome of the H1 hESCs indicated that activation of KLF1
promoted the differentiation of erythroid cells as assessed by
an increase in the proportion of CD235a1 CD711 expressing
cells and an increase in the level of CD235a expression (Sup-
porting Information Fig. S3). However, given the known silenc-
ing issues associated with random integration of transgenes
and the potential detrimental effects of insertion mutagene-
sis, we adopted a ‘safe harbor’ approach and targeted the
CAG-HA-KLF1-ERT2 transgene to the AAVS1 locus (Fig. 3A)
[34]. We generated the AAVS1-HA-KLF1-ERT2 targeting vector
(Fig. 3A) and electroporated this together with the AAVS1 zinc
finger nuclease (ZFN) plasmids (a gift from Dr C.J. Chang,
Icahn School of Medicine at Mount Sinai, New York) [33, 35]
into the human iPSC line, SFCi55 (Supporting Information Fig.
S2). Puromycin-resistant colonies were screened by genomic
PCR (Supporting Information Fig. S4). 93% (27/29) of iPSC
clones were correctly targeted with both AAVS1 alleles tar-
geted in 13 clones (Supporting Information Fig. S4A-4G).
Western blot analyses using the a2HA antibody detected the
fusion protein in targeted iPSC clones (herein referred to as
iKLF1.1 and iKLF1.2) (Supporting Information Fig. S5A). We
confirmed the presence of the predicted sized KLF1-ERT2
fusion protein in nuclear extracts isolated from undifferentiat-
ed and differentiated (day 10) iKLF1.2 iPSCs and noted that
the level of expression of KLF1 protein in day 10 differentiat-
ing iPSCs was significantly lower than in adult CD341 cells
(Fig. 3B) as was the level of KLF1 transcript (Supporting Infor-
mation Fig. S5C) as previously demonstrated (Supporting
Information Fig. S1). We noted the presence of a low level of
KLF1-ERT2 fusion protein in our crude nuclear extracts in the
absence of tamoxifen but it is unclear whether this is due to
cytoplasmic contamination or leakiness of the ERT2 system
(Fig. 3B). Addition of tamoxifen for 3 hours resulted in the
translocation of KLF1-ERT2 protein into the nucleus (Fig. 3B).
The level KLF1 protein expression in differentiating iKLF1.2
iPSCs is comparable to the level of expression of endogenous
KLF1 in differentiating adult CD341 cells indicating that, unlike
lentiviral expression strategies that result in very high, non-
physiological levels of transgene expression, this strategy
results in physiological levels of KLF1 (Fig. 3B, Supporting
Information Fig. S5C).
The clonal iKLF1.2 iPSC line was differentiated using the
erythroid differentiation protocol [36] and we assessed the
production of erythroid cells at day 15 in the presence and
absence of tamoxifen (from day 10). Upon activation of KLF1,
the percentage of CD235a1 CD711 double positive erythroid
cells increased in the iKLF1.2 iPSC lines, but not in control
iPSCs (Fig. 3C, 3D). This increase was also observed in the
independently derived iKLF1.1 cell line (Supporting Informa-
tion Fig. S5B) and was consistent with the results using ran-
domly inserted constructs in hESCs (Supporting Information
Figure 4. Activation of KLF1 enhances erythroid differentiation at the expense of cell proliferation. (A): Cell numbers of control and
iKLF1.2 induced pluripotent stem cells (iPSCs) during erythroid differentiation. 3 3 105 cells were seeded at day 10 of differentiation
then further differentiated in the presence or absence of tamoxifen. Data represent the mean of three independent experiments and
error bars represents SEM. p values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test (*p< .05).
(B): Flow cytometry analysis using LIVE/DEAD Fixable Near-IR Stain of viable cells present at day 15, 24, and 31 of the erythroid differen-
tiation protocol in control iPSCs and iKLF1.2 iPSC cell lines in the presence (1) and absence (2) of tamoxifen from day 10. (C): Quanti-
tative reverse-transcriptase polymerase chain reaction analyses of RNA isolated from control (iPSC) and iKLF1 iPSC (iKLF1.2) at day 24
following treatment with (1) or without (2) tamoxifen from day 10 using primers to BCLX, PIM1 and E2F2, p21, p27, and p18. Data
represent the mean of three independent experiments and error bars show the SEM. For each gene, the expression level of control
iPSCs in the absence of tamoxifen was used as the calibrator and set at 1 and the expression of all other samples expressed as fold
change. A ratio paired t test was used to assess the effect of KLF1 activation in iKLF1.2 cells (*p< .05 **p< .005). Abbreviation: iPSCs,
induced pluripotent stem cells.
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Fig. S3A). These data indicate that activation of KLF1
enhanced erythroid differentiation, visually evident by the
enhanced red appearance of the cell pellet (Fig. 3E). We also
noted that tamoxifen treated cultures generated a smaller cell
pellet and a significantly lower number of cells (Fig. 4A).
There was no significant difference in cell viability at days 15,
24, and 31 when KLF1 was activated at day 10 indicating that
the reduced cell number was not the result of increased apo-
ptosis or cell death. (Fig. 4B). Furthermore, quantitative
reverse-transcriptase polymerase chain reaction analyses of
differentiating cells (day 24) demonstrated that activation of
KLF1 resulted in a significant upregulation of the cell cycle
inhibitors P21 and P27, the anti-apoptotic gene, BCLX and
PIM1 that regulates cell proliferation and survival (Fig. 4C).
Interestingly KLF1 activation did not result in the upregulation
of P18 which has been shown to mediate the effects of KLF1
effect on cell cycle exit in the murine system [39]. Taken
together, our data suggest that activation of KLF1 promotes
erythroid differentiation at the expense of cell proliferation.
Activation of KLF1 Enhanced the Expression of Genes
Associated with Erythropoiesis
To investigate the impact of KLF1 activation on genes associat-
ed with erythropoiesis, we conducted real-time PCR on RNA
isolated from differentiating control hiPSCs and iKLF1.2 at day
15 in the presence or absence of tamoxifen from day 10
(Fig. 5A, Supporting Information Fig. S6A). Activation of KLF1
significantly increased the expression of the erythroid tran-
scription factor-encoding gene, SOX6 consistent with the
higher proportion of erythroid cells. Consistent with our find-
ings in K562 cells, expression of the known KLF1 target gene
AHSP was significantly upregulated upon KLF1 activation.
Interestingly the expression of BCL11A, a known target gene
of KLF1 was not enhanced in this assay but this is possibly
explained by the fact that these cells have a “primitive”-like
signature (see below). The expression of KLF1 target genes
associated with RBC maturation was also analyzed at a later
stage in the differentiation process (day 24) (Fig. 5B, Support-
ing Information Fig. S6B). At this time point, expression of
genes associated with cell membrane and cytoskeleton,
including ANK1, GYPC, and SLC4A1 were significantly increased
upon KLF1 activation but there was no significant increase in
the expression of SLC2A4 nor EPB4.9. The expression of
ABCG2 that is involved in transport and heme synthesis was
also upregulated by KLF1 activation. The above results suggest
KLF1 activation from day 10 increased the maturity of ery-
throid cells and accelerated the process of erythropoiesis.
KLF1-Activated Erythroid Cells Express Embryonic
Globins
HPLC analyses of protein isolated from cells at day 31 of the
differentiation protocol showed that activation of KLF1 in
iKLF1.2-derived erythroid cells significantly enhanced the pro-
portion of the embryonic e- and f-globin and reduced the
proportion of g-globin protein. No adult b-globin protein was
detected in any of the samples (Fig. 6). Taken together these
data suggests that, in this differentiation system, activation of
KLF1 at day 10 of the differentiation protocol enhances the
production and maturation of primitive erythroid cells.
KLF1 Activation Increases the Proportion of Enucleated
Erythroid Cells
Given previous reports that KLF1 null mice had more nucleated
RBCs [25], we hypothesized that activation of exogenous KLF1
might enhance the efficiency of maturation and/or their stabili-
ty. Differentiating KLF1-ERT2-expressing cells were treated with
Figure 5. A subset of KLF1 target genes are upregulated upon activation of KLF1 during erythroid differentiation. Quantitative reverse-
transcriptase polymerase chain reaction analyses of RNA isolated from control induced pluripotent stem cell (iPSC) and iKLF1 iPSC
(iKLF1.2) at day 15 (A) and day 24 (B) following treatment with (1) or without (2) tamoxifen from day 10 using primers to SOX6, AHSP,
BCL11A, ANK1, GYPC, SLC4A1, SLC2A4, EPB4.9, and ABCG2. Data represent the mean of three independent experiments and error bars
show the SEM. For each gene, the expression level of control iPSCs in the absence of tamoxifen was used as the calibrator and set at 1
and the expression of all other samples expressed as fold change. A ratio paired t test was used to assess the effect of KLF1 activation
in iKLF1.2 cells (*p< .05). Abbreviation: iPSCs, induced pluripotent stem cells.
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tamoxifen then the presence of enucleate cells assessed by flow
cytometry. Live CD235a1 cells were gated and CD235a1/
CD711/Hoechst1 erythroblasts, CD235a1/CD712/Hoechst1
nucleated RBCs and CD235a1/CD712/Hoechst2 enucleated
RBCs were identified (Supporting Information Fig. S7). Human
peripheral blood was used as a positive control for the identifi-
cation of live, CD235a1/CD712/Hoechst- enucleated RBCs. The
majority of differentiating cells at day 24 were nucleated
Figure 6. Activation of KLF1 enhances the production erythroid cells expressing embryonic globins. Results of HPLC analysis of globin
proteins in cell lysates isolated from control induced pluripotent stem cells and iKLF1.2 cells at day 31 of the differentiation protocol in
the presence (1) or absence (2) of tamoxifen from day 10. Data represent the mean of three independent experiments and error bars
represents SEM. p values were calculated using two-way ANOVA followed by Tukey’s multiple comparisons test. (*p< .05). Abbreviation:
iPSCs, induced pluripotent stem cells.
Figure 7. KLF1 activation increases the proportion of detectable enucleated cells. (A, B): CD71 and Hoechst staining of live, CD235a
gated cells at day 24 (A) and day 31 (B) derived from control induced pluripotent stem cell (iPSC) and KLF1-ERT2-expressing (iKLF1.2)
cells in the presence and absence of tamoxifen. Control enucleated cells derived from adult peripheral blood is shown. (see Supporting
Information Fig. S7 for gating strategy) (C) Quantification of the proportion of enucleated cells at day 31 of control iPSCs and iKLF1.2
cells in the presence and absence of tamoxifen. Data represent the mean of three independent experiments and error bars represents
SEM. p values were calculated using one-way ANOVA followed by Holm-Sidak’s multiple comparison test (*p< .05). (D): Cytospins of
day 31 cells demonstrating the more robust phenotype of iKLF1 cells after tamoxifen treatment and the presence of some enucleated
cells (arrows) (Magnification x40). Abbreviation: iPSCs, induced pluripotent stem cells.
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CD235a1/CD711/Hoechst1 erythroblasts (Fig. 7A). By day
31 CD235a1 cells began to lose the CD71 marker, indicating
that they represented a more mature erythroid population (Fig.
7B). Activation of KLF1 in differentiating iPSCs reproducibly
increased the proportion of enucleated RBCs that were detected
in this assay (Fig. 7B, 7C). Morphological analyses indicated that
that KLF1-activated cells had a more robust morphology which
could explain the fact that more enucleated cells were detected
(Fig. 7D).
DISCUSSION
Current protocols to produce RBCs from hPSC have limitations
because they generate a relatively low proportion of enucleated
cells and express embryonic/foetal but not adult globin [6]. For-
ward programming using lineage specific transcription factors
has been used to enhance the production of a number cell
types from hPSCs including hematopoietic lineages [16, 17, 40].
Here we describe the first application of an inducible program-
ming strategy to modify the production and maturation of RBCs
from hPSCs. We used the transcription factor KLF1 because it
was expressed at low levels in hPSC-derived erythroid cells com-
pared adult-derived cells and it plays a pivotal role in the final
steps of definitive erythropoiesis [19]. Genes that are regulated
by KLF1 include many of the key genes associated with ery-
throid development and maturation [19, 25, 41, 42].
We established an inducible activation strategy whereby
the exogenous KLF-ERT2 fusion protein is tethered in the cyto-
plasm but upon addition of tamoxifen it can translocate to
the nucleus and activate the expression of target genes. The
level expression of KLF1 in differentiating iKLF1.2 iPSCs is
comparable to the level of expression in differentiating adult
CD341 cells indicating that physiological levels of expression
are achieved using this strategy.
Activation of KLF1 at day 10 after HPC formation resulted
in an increase in the proportion of erythroid cells but the
overall number of cells was lower than controls. The fact that
we observed no effect on the viability of cells suggests that
activation of KLF1 is driving HPCs to differentiate at the
expense of proliferation [43]. It is well documented that ery-
throid terminal differentiation requires proliferation arrest and
exit from the cell cycle with a balance between proliferation
and maturation being fine-tuned at later stages of erythropoi-
esis [24, 44]. The antiproliferative effect of KLF1 during eryth-
ropoiesis is thought to be via its interactions with cell cycle
related genes including PIM1, E2F2, p27, p21, p18 [19, 39,
45]. We demonstrate that activation of KLF1 significantly
altered the expression levels of p27, p21, and PIM1 but not
p18 suggesting that some, but not all, of these interactions
are conserved between mouse and human. Our results are
consistent with a study using a similar KLF1-ERT2 strategy in
murine ESCs where activation of KLF1 resulted in reduced
proliferation coupled with enhanced differentiation [46].
Another study using a tetracycline-inducible KLF1 strategy in
murine ESCs expression reported that KLF1 promoted the
expression of erythroid lineage genes while repressing the
onset of megakaryopoiesis [43]. We detected an increase in
expression of KLF1 target genes associated with heme synthe-
sis and transport including ABCG2 and AHSP, supporting the
notion that KLF1-activation enhanced the erythroid matura-
tion and differentiation process.
Activation of exogenous KLF1 resulted in an increase in
the proportion of detectable enucleated erythroid cells. It has
been proposed that hPSC-derived erythroid cells may be more
fragile than their counterparts generated from adult CD34
progenitors [36] and so it is possible that the effect of KLF1 is
due to enhanced membrane stability rather than a direct
effect on the enucleation process per se. The final stages of
RBC maturation are associated with cell membrane and cyto-
skeleton remodelling and a number of KLF1 target genes have
been associated with these processes [19, 21, 26, 47]. Fur-
thermore, the phenotype of KLF1 deficient mice has been
associated with decreased membrane stability [21]. Activation
of KLF1 in our system enhanced the expression of some of
these KLF1 targets including ANK1, GYPC, SLC4A1, and ABCG2
which supports our hypothesis that activation of KLF1 results
in the production of more robust erythroid cells.
The mechanisms of enucleation is known to involve multi-
ple molecular and cellular pathways including histone deace-
tylation, actin polymerization, cytokinesis, cell-matrix
interactions, specific microRNAs, and vesicle trafficking [48].
Enucleation efficiency of iPSC-derived erythroid cells was
improved with stromal cell culture and when cells were
derived from cultures involving prolonged three-dimensional
culture [1, 5]. More recently KLF1 has been shown to have an
extrinsic role in erythroid maturation via expression of KLF1 in
erythroid-island associated macrophages [49, 50] so KLF1 may
be playing an extrinsic role during the differentiation process.
It is also possible that KLF1 activation is altering the expres-
sion of miRNAs or long noncoding RNAs that have been iden-
tified as key players in erythroid development and maturation
[1, 51].
The majority of hPSC differentiation protocols generate
RBCs that express embryonic e-globins and/or foetal g-
globins, but little or no adult b-globin [6, 7]. We show that
KLF1 enhanced the expression of embryonic e- and f-globin
proteins, but no adult b-globin was detected in any of the
conditions suggesting that this strategy is enhancing the pro-
duction of embryonic erythroid cells and that KLF1 alone is
not sufficient to enhance the expression of adult b-globin. A
low level of expression of KLF1 and BCL11A in K562 cell and
cord blood derived erythroid cells was shown to be associated
with fetal globlin expression and transduction of KLF1 and
BCL11A lentiviral vectors resulted in adult levels of b2globin
in these cells [52]. Interestingly that study also demonstrated
that lentiviral transduction of BCL11A alone was sufficient to
induce the expression of b2globin in the immortalized iPSC-
derived HiDEP-1 cell line because that cell lines had adult-like
levels of KLF1 [52]. A recent study that added KLF1 to iEP
cells showed adult-like globin [17]. The erythroid cells derived
from the SFCi55 iPSC cell line used in this study have lower
levels of KLF1 compared to differentiated adult CD341 cells
(Fig. 3B, Supporting Information Fig. S5C) and, although
BCL11A has been reported as a KLF1 target gene, we did not
see a significant alteration in the level of expression of
BCL11A upon KLF1 activation in our system. Activation of
KLF1 target genes will rely on the presence of specific cofac-
tors which will be cell context dependent. More recent stud-
ies highlight the complexity of interaction between KLF1 and
its regulated genes and specialized transcription factories in
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nuclear hotspots have been identified that are likely where
coregulated genes cooperate for optimal efficiency and coor-
dinated transcriptional control [20]. Our ongoing studies are
assessing the effects of exogenous expression of both KLF1
and BCL11A on the expression of the different globin proteins
in differentiating iPSCs.
Flow cytometry analyses of erythroid markers throughout
the differentiation protocol indicates that there are two waves
of erythropoiesis in our culture system [36] and our data sug-
gest that activation of KLF1 at day 10 is enhancing the primi-
tive rather than the definitive wave.
This study is the first to demonstrate enhanced erythropoie-
sis from hPSCs using a forward programming approach by acti-
vation of a single transcription factor, KLF1 at levels that are
comparable to physiological level. However, the successful pro-
duction of adult-like erythroid cells in sufficient quantities from
iPSCs will undoubtedly require the use of multiple transcription
factors in a combinatorial forward programming approach as
recently described for the production of platelets form hPSCs
[40] and primitive erythroid cells from fibroblasts [17]. The key
to this strategy is to define the complex cocktail of transcription
factors that define the development and maintenance of adult
erythroid cells and to induce their expression at defined time-
points in a reproducible manner. Integration of inducible tran-
scription factors into the AAVS1 locus could provide a safer and
more reproducible strategy for clinical translation.
This study assessed the effects of KLF1 on the production
and maturation of erythroid cells from differentiating human
pluripotent stem cells. We generated a human iPSC line carrying
a tamoxifen-inducible form of KLF1 in the AAVS1 locus. Activa-
tion of KLF1 alone promoted erythroid differentiation,
enhanced the expression of key erythroid genes and generated
a slightly higher proportion of mature enucleated cells.
However, activation of KLF1 promoted the differentiation of
primitive, not definitive erythroid cells as defined by an increase
in embryonic globins. The enhanced erythroid differentiation is
associated with a proliferation arrest and the upregulation of
the cell cycle inhibitors P21 and P27 resulting in a significant
reduction in the overall number of cells generated.
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